{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["88(9)"],"submitter":["Foreman E"],"pubmed_abstract":["<h4>Aims</h4>The aim of this study is to investigate the rates of hypersensitivity reactions (HSRs) in patients receiving paclitaxel chemotherapy, with and without a histamine-2 (H<sub>2</sub> ) antagonists.<h4>Method</h4>This prospective, multi-centre, cohort study compared patients receiving paclitaxel treated with premedication regimens containing chlorphenamine, dexamethasone and an H<sub>2</sub> antagonist vs patients treated without an H<sub>2</sub> antagonist. Rates of HSRs were described and logistic multivariable regression was used to investigate any associations with H<sub>2</sub> antagonist treatment, adjusting for confounding variables.<h4>Results</h4>A total of 1043 individuals were included in the study; of these, 638 (61%) patients received an H<sub>2</sub> antagonist and 405 (49%) were not given an H<sub>2</sub> antagonist. Incidence of HSR in the cohort treated with H<sub>2</sub> antagonists was 11.31% (n = 70) vs 9.86% (n = 41) in the cohort without. There was no statistically significant difference between the rates of HSR observed in those receiving and not receiving an H<sub>2</sub> antagonist (odds ratio 1.04, 95% CI 0.65, 1.66, P = .9).<h4>Conclusions</h4>Results presented within the study are consistent with other recently published evidence to suggest that H<sub>2</sub> antagonists do not confer any advantage as part of premedication regimens in reducing the incidence of HSR in patients treated with paclitaxel."],"journal":["British journal of clinical pharmacology"],"pagination":["4191-4198"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9545865"],"repository":["biostudies-literature"],"pubmed_title":["Histamine-2 (H<sub>2</sub> ) antagonists can be safely removed from standard paclitaxel premedication regimens."],"pmcid":["PMC9545865"],"pubmed_authors":["Foreman E","Walker A","Chambers P","Polwart C"],"additional_accession":[]},"is_claimable":false,"name":"Histamine-2 (H<sub>2</sub> ) antagonists can be safely removed from standard paclitaxel premedication regimens.","description":"<h4>Aims</h4>The aim of this study is to investigate the rates of hypersensitivity reactions (HSRs) in patients receiving paclitaxel chemotherapy, with and without a histamine-2 (H<sub>2</sub> ) antagonists.<h4>Method</h4>This prospective, multi-centre, cohort study compared patients receiving paclitaxel treated with premedication regimens containing chlorphenamine, dexamethasone and an H<sub>2</sub> antagonist vs patients treated without an H<sub>2</sub> antagonist. Rates of HSRs were described and logistic multivariable regression was used to investigate any associations with H<sub>2</sub> antagonist treatment, adjusting for confounding variables.<h4>Results</h4>A total of 1043 individuals were included in the study; of these, 638 (61%) patients received an H<sub>2</sub> antagonist and 405 (49%) were not given an H<sub>2</sub> antagonist. Incidence of HSR in the cohort treated with H<sub>2</sub> antagonists was 11.31% (n = 70) vs 9.86% (n = 41) in the cohort without. There was no statistically significant difference between the rates of HSR observed in those receiving and not receiving an H<sub>2</sub> antagonist (odds ratio 1.04, 95% CI 0.65, 1.66, P = .9).<h4>Conclusions</h4>Results presented within the study are consistent with other recently published evidence to suggest that H<sub>2</sub> antagonists do not confer any advantage as part of premedication regimens in reducing the incidence of HSR in patients treated with paclitaxel.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-22T01:58:21.197Z","creation":"2025-04-05T20:11:06.839Z"},"accession":"S-EPMC9545865","cross_references":{"pubmed":["35470452"],"doi":["10.1111/bcp.15363"]}}